NasdaqCM - Nasdaq Real Time Price USD

Bone Biologics Corporation (BBLG)

0.8013

-0.0267

(-3.22%)

As of 12:53:57 PM EDT. Market Open.

BBLG Entering Critical Stage in Good Shape

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s 1Q 2025 financial results and while a company at this stage is far more reliant on testing products, which is discussed below and advancing rapidly, the financial picture is also vital. This quarter’s release shows that the company has made further advances in controlling

Zacks Small Cap Research 23 days ago

BBLGW
BBLG Continues Crucial Testing

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s full year 2024 financial results and while a company at this stage is far more reliant on testing of products, which is discussed below and advancing rapidly, the financial picture is also vital. This year’s release shows that the company has made further advances in

Zacks Small Cap Research 3 months ago

BBLGW
BBLG in Good Shape as Testing Continues

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s 3Q 2024 financial results and while a company at this stage is far more reliant on testing of products, which is discussed below and advancing nicely, the financial picture is also vital. This quarter’s release shows that the company has made further advances in

Zacks Small Cap Research 6 months ago

BBLGW
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

BURLINGTON, Mass., October 21, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four.

Business Wire 7 months ago

BBLG
-3.22%

BBLGW
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BURLINGTON, Mass., September 04, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics’ company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern t

Business Wire 8 months ago

BBLG
-3.22%

BBLGW
LifeNet launches newest bone allograft gel with Johnson & Johnson

Designed in Virginia and commericalised by Johnson & Johnson, Lifenet Health’s bone allograft is aims to help surgeons expedite procedures.

Medical Device Network 9 months ago

JNJ

BBLGW
BBLG: Controls Costs and Advances Trials

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s 2Q 2024 financial results and while a company at this stage is far more reliant on testing of products, which is discussed below and advancing nicely, the financial picture is also vital. This quarter’s release shows that the company has made advances in controlling expenses

Zacks Small Cap Research 9 months ago

BBLGW
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

BURLINGTON, Mass., August 02, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exerci

Business Wire 9 months ago

BBLG
-3.22%

BBLGW
OTC Markets Hosts Virtual Investor Presentation with Jeff Frelick, CEO and President of Bone Biologics, and Deina Walsh, CFO, with Brad Sorensen, Senior Analyst at Zacks SCR

NASDAQ:BBLG Matt Liteplo: Hello, and welcome to Virtual Investor Conferences. My name is Matt Liteplo, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you have joined us for our next live presentation from Bone Biologics Corp. Brad Sorensen, CFA Senior Equity Research Analyst with Zacks Small Cap Research, will moderate the session. Note that you can

Zacks Small Cap Research 10 months ago

BBLGW
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20th are now available for online viewing. REGISTER NOW AT: https://bit.ly/4cbVF5U The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download in

GlobeNewswire 11 months ago

LGVN

LGVNR

GLABF
First patients treated in Bone Biologics spinal fusion trial

The multicentre trial will see 30 adults living with degenerative disc disease treated with the company’s NB1 device designed to regenerate bone faster

Medical Device Network 11 months ago

BBLGW
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion

BURLINGTON, Mass., June 20, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration.

Business Wire 11 months ago

BBLG
-3.22%

BBLGW
BBLG Marks Important Milestone

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT We have been discussing the promising initial results of the Bone Biologics (NASDAQ:BBLG) treatment known as NB1, and now the company has announced an important milestone—the first two human patients have been treated in the company’s NB1 bone graft device. This marks the start of the pilot clinical study that will evaluate NB1

Zacks Small Cap Research 11 months ago

BBLGW
Life Sciences Virtual Investor Forum Agenda Announced for June 20th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20th, 2024. This event is co-sponsored by Zack’s Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4bUev

GlobeNewswire 11 months ago

GLABF

BBLG
-3.22%

BBLGW
Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th

BURLINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, the Company’s president and chief executive officer, and Deina Walsh, chief financial officer, will be interviewed by Zacks Small-Cap Research analyst Brad Sorensen, CFA in a “CEO Chat” on June 20th at the Life Science Investor Forum with Virtual Investor Conferenc

GlobeNewswire 11 months ago

BBLG
-3.22%

BBLGW

Performance Overview

Return	BBLG	S&P 500 (^GSPC)
YTD	-14.76%	+1.42%
1-Year	-50.84%	+11.41%
3-Year	-99.79%	+45.19%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bone Biologics Corporation (BBLG)

BBLG Entering Critical Stage in Good Shape

BBLG Continues Crucial Testing

BBLG in Good Shape as Testing Continues

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

LifeNet launches newest bone allograft gel with Johnson & Johnson

BBLG: Controls Costs and Advances Trials

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

OTC Markets Hosts Virtual Investor Presentation with Jeff Frelick, CEO and President of Bone Biologics, and Deina Walsh, CFO, with Brad Sorensen, Senior Analyst at Zacks SCR

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

First patients treated in Bone Biologics spinal fusion trial

First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion

BBLG Marks Important Milestone

Life Sciences Virtual Investor Forum Agenda Announced for June 20th

Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th

Performance Overview